NDA 018689 · Legacy
Ridaura
Auranofin · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: May 14, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
May 24, 1985
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
0 Phase 3, 2 recruiting
FAERS reports
205
156 serious, 28 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
RIDAURA ® (auranofin) contains gold and, like other gold-containing drugs, can cause gold toxicity, signs of which include: fall in hemoglobin, leukopenia below 4,000 WBC/cu mm, granulocytes below 1,500/cu mm, decrease in platelets below 150,000/cu mm, proteinuria, hematuria, pruritus, rash, stomatitis or persistent diarrhea. Therefore, the results of recommended laboratory work (See PRECAUTIONS ) should be reviewed before writing each RIDAURA prescription. Like other gold preparations, RIDAURA is only indicated for use in selected patients with active rheumatoid arthritis. Physicians planning to use RIDAURA should be experienced with chrysotherapy and should thoroughly familiarize themselves with the toxicity and benefits of RIDAURA. In addition, the following precautions should be routinely employed: The possibility of adverse reactions should be explained to patients before starting...
What it is approved for
From the label in effect Nov 8, 2025.
INDICATIONS AND USAGE RIDAURA (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies. Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months. When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active synovitis, particularly in its early stage. In controlled clinical trials comparing RIDAURA with injectable gold, RIDAURA was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of RIDAURA in patients who are candidates for chrysotherapy.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 24, 1985 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
- RIDAURA · AURANOFIN 3MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Auranofin" as an intervention, any sponsor and status, largest first.
- TB Host Directed TherapyPivotal-lookingStatus unknown
The Aurum Institute NPCAcademic, hospital or other
NCT02968927 · 200 participants · Start Nov 2016 · Primary completion Sep 2018
Drug: Everolimus 0.5 MG; Auranofin 6 MG and 3 more · For: Tuberculosis
Sites: Tembisa, South Africa
- Auranofin for Giardia ProtozoaCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02736968 · 93 participants · Start Nov 6, 2016 · Primary completion Mar 10, 2021
Drug: Auranofin · For: Amoebic Dysentery; Giardiasis
Sites: Dhaka, Bangladesh; Rajshahi, Bangladesh
Federal University of São PauloAcademic, hospital or other
NCT06805656 · 70 participants (planned) · Start Jul 15, 2026 · Primary completion Mar 1, 2027
Drug: Maraviroc; Dolutegravir and 3 more · For: Hiv; HIV I Infection
Sites: São Paulo, Brazil
Mayo ClinicAcademic, hospital or other
NCT02063698 · 30 participants · Start Feb 19, 2014 · Primary completion Nov 11, 2015
Drug: auranofin · For: Pain
Sites: Rochester, Minnesota
Federal University of São PauloAcademic, hospital or other
NCT02961829 · 30 participants · Start Jul 2015 · Primary completion Mar 2019
Drug: Maraviroc; Dolutegravir and 3 more · For: Chronic Infection; HIV
Sites: São Paulo, Brazil
Mayo ClinicAcademic, hospital or other
NCT01737502 · 29 participants · Start May 14, 2014 · Primary completion Apr 24, 2023
Drug: Auranofin; Sirolimus · For: Extensive Stage Small Cell Lung Carcinoma; Lung Adenocarcinoma; Recurrent Non-Small Cell Lung Carcinoma and 5 more
Sites: Scottsdale, Arizona; Jacksonville, Florida
Mayo ClinicAcademic, hospital or other
NCT03456700 · 22 participants · Start Mar 30, 2018 · Primary completion Jul 31, 2019
Drug: Auranofin; Sirolimus · For: Ovarian Serous Tumor; Recurrent Ovarian Carcinoma
Sites: Rochester, Minnesota
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02089048 · 15 participants · Start Apr 2, 2014 · Primary completion Sep 9, 2014
Drug: Auranofin · For: Amoebiasis
Sites: Overland Park, Kansas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity18
- drug ineffective16
- nausea15
- anaemia12
- fall11
- fatigue11
- pneumonia11
- pain10
- pyrexia9
- myocardial infarction8
- rheumatoid arthritis8
- abdominal pain upper7
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 21 |
| 2006 | 11 |
| 2007 | 8 |
| 2008 | 15 |
| 2009 | 14 |
| 2010 | 8 |
| 2011 | 9 |
| 2012 | 7 |
| 2013 | 11 |
| 2014 | 9 |
| 2015 | 1 |
| 2016 | 10 |
| 2017 | 18 |
| 2018 | 22 |
| 2019 | 10 |
| 2020 | 4 |
| 2021 | 4 |
| 2023 | 1 |
| 2024 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ridaura (Auranofin)
2024 spending
$922K
Beneficiaries
88
635 claims
Per beneficiary
$10,482
$25.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,202,667 |
| 2021 | $1,072,420 |
| 2022 | $1,074,965 |
| 2023 | $993,665 |
| 2024 | $922,395 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Auranofin.
Davis P · Clin Rheum Dis 1984 · Clinical Trial, Comparative Study
- Interventions for psoriatic arthritis.
Jones G, Crotty M, Brooks P · Cochrane Database Syst Rev 2000 · Systematic Review
- Interventions for psoriatic arthritis.
Jones G, Crotty M, Brooks P · Cochrane Database Syst Rev 2000 · Systematic Review
- Auranofin (Ridaura).
· Med Lett Drugs Ther 1985 · Clinical Trial
- Auranofin versus placebo in rheumatoid arthritis.
Suarez-Almazor ME, Spooner CH, Belseck E, et al. · Cochrane Database Syst Rev 2000 · Systematic Review
- Auranofin: a unique oral chrysotherapeutic agent.
Blodgett RC, Heuer MA, Pietrusko RG · Semin Arthritis Rheum 1984 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.